Patricia Brett
SubscribersAbout
Results of studies have shown that hormone therapy, when taken for 5 years or more, can greatly reduce the risk of new breast cancer, breast cancer recurrence, and dying from breast cancer. Refusing or stopping hormone therapy is your decision, but research has shown that hormone therapy can effectively lower your risk of new and recurrent breast cancer and of dying from breast cancer. Some people with advanced breast cancer are treated with a combination of hormone therapy and targeted therapy. Hormone therapy is also an option for people with ER-positive breast cancer that has come back in the breast, chest wall, or nearby lymph nodes after treatment (also called a locoregional recurrence). Men with early-stage ER-positive breast cancer who receive adjuvant therapy are usually treated first with tamoxifen. Your doctor may prescribe hormone therapy after surgery (adjuvant therapy) to reduce your risk of new or recurrent breast cancer.
The Harvard researchers developed a specific protocol for a golden retriever named Navy who was cancer-free after receiving the prescribed cocktail of celecoxib, doxycycline, and tamoxifen – the treatment subsequently became known as the Navy Protocol. Upon discontinuation of treatment, levels of tamoxifen and its metabolites persist in the circulation for at least 6 weeks. Endoxifen levels have been reported as 10.8 to 15.9 ng/mL at steady state in CYP2D6 normal metabolizers during therapy with 20 mg/day tamoxifen. Due to the nature of tamoxifen as a competitive ER ligand, this increase in estrogen levels is liable to interfere with the antiestrogenic efficacy of tamoxifen. Tamoxifen is antigonadotropic in postmenopausal women and partially suppresses levels of the gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in such women. Tamoxifen needs to block growth factor proteins such as ErbB2/HER2 because high levels of ErbB2 have been shown to occur in tamoxifen resistant cancers.
The breast cancer cells have receptors (proteins) that attach to estrogen and progesterone, which helps them grow. Some types of breast cancer are affected by hormones, like estrogen and progesterone. This is an older drug and is usually reserved for men whose cancer is no longer responding to other forms of hormone therapy.
When testosterone levels fall below the optimal range, it can lead to a condition called hypogonadism or low testosterone. When testosterone levels dip, it can have a significant impact on overall well-being. SERMs and AIs have been used off-label in men to increase testosterone levels while maintaining spermatogenesis. There have been significant advancements in understanding the interaction between testosterone and estrogen and how these two hormones impact multiple physiologic functions in men. It is hypothesized that gynecomastia occurs from an alteration in the estrogen to androgen ratio at the level of the breast.42 Tamoxifen, given its estrogen antagonist properties in the breast, as well as AIs, has also been used in the treatment of gynecomastia. Perhaps with prolonged exposure to lower estrogen levels bone mineral density may decrease over time or there may be estrogen receptor polymorphisms that make some men susceptible to lower bone mineral density.35 Despite their success, there are no long-term data evaluating the efficacy of AIs and, therefore, their use for hypogonadism cannot be routinely recommended at this time.
However, if you are worried about your balls shrinking during the cycle, you could use HCG to reverse those adverse effects. Prevention is better than treatment when it comes to gyno, so taking a proactive approach rather than waiting for any symptoms of breast growth to happen is critical. The best way to reduce or eliminate your risk of long-term side effects when using Nolvadex is to keep the dosage at sensible levels. Again, individual response and any interactions with other drugs being used can influence your personal experience with Nolvadex. Every drug on earth will cause side effects in some users, and Nolvadex is no exception.
Nolvadex is known for its excellent ability to stimulate testosterone levels while blocking the effect of estrogen, enabling greater amounts of luteinizing hormone (LH) released by the pituitary gland. Traditional aromatase inhibitor drugs often used for gynecomastia in male bodybuilders come with significant risks to your cholesterol and in crushing your estrogen levels. So those steroids that do aromatize need to have these effects addressed; otherwise, you get out-of-control estrogen conversion, rising estrogen levels, and lower testosterone levels. In contrast, SERMs like Nolvadex, Clomid, and Toremifene are only effective at controlling gyno because these drugs were developed to target breast tissue estrogen receptors. Both are valued and used for their beneficial effects in reducing or preventing estrogen-related side effects of steroids and to assist with restoring testosterone function as part of post-cycle therapy. A clinical strategy was described that led to the creation of SERMs as a group of multifunctional medicines aimed at the treatment or prevention of many conditions in postmenopausal women, e.g. osteoporosis and breast cancer.
The Harvard researchers developed a specific protocol for a golden retriever named Navy who was cancer-free after receiving the prescribed cocktail of celecoxib, doxycycline, and tamoxifen – the treatment subsequently became known as the Navy Protocol. Upon discontinuation of treatment, levels of tamoxifen and its metabolites persist in the circulation for at least 6 weeks. Endoxifen levels have been reported as 10.8 to 15.9 ng/mL at steady state in CYP2D6 normal metabolizers during therapy with 20 mg/day tamoxifen. Due to the nature of tamoxifen as a competitive ER ligand, this increase in estrogen levels is liable to interfere with the antiestrogenic efficacy of tamoxifen. Tamoxifen is antigonadotropic in postmenopausal women and partially suppresses levels of the gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in such women. Tamoxifen needs to block growth factor proteins such as ErbB2/HER2 because high levels of ErbB2 have been shown to occur in tamoxifen resistant cancers.
The breast cancer cells have receptors (proteins) that attach to estrogen and progesterone, which helps them grow. Some types of breast cancer are affected by hormones, like estrogen and progesterone. This is an older drug and is usually reserved for men whose cancer is no longer responding to other forms of hormone therapy.
When testosterone levels fall below the optimal range, it can lead to a condition called hypogonadism or low testosterone. When testosterone levels dip, it can have a significant impact on overall well-being. SERMs and AIs have been used off-label in men to increase testosterone levels while maintaining spermatogenesis. There have been significant advancements in understanding the interaction between testosterone and estrogen and how these two hormones impact multiple physiologic functions in men. It is hypothesized that gynecomastia occurs from an alteration in the estrogen to androgen ratio at the level of the breast.42 Tamoxifen, given its estrogen antagonist properties in the breast, as well as AIs, has also been used in the treatment of gynecomastia. Perhaps with prolonged exposure to lower estrogen levels bone mineral density may decrease over time or there may be estrogen receptor polymorphisms that make some men susceptible to lower bone mineral density.35 Despite their success, there are no long-term data evaluating the efficacy of AIs and, therefore, their use for hypogonadism cannot be routinely recommended at this time.
However, if you are worried about your balls shrinking during the cycle, you could use HCG to reverse those adverse effects. Prevention is better than treatment when it comes to gyno, so taking a proactive approach rather than waiting for any symptoms of breast growth to happen is critical. The best way to reduce or eliminate your risk of long-term side effects when using Nolvadex is to keep the dosage at sensible levels. Again, individual response and any interactions with other drugs being used can influence your personal experience with Nolvadex. Every drug on earth will cause side effects in some users, and Nolvadex is no exception.
Nolvadex is known for its excellent ability to stimulate testosterone levels while blocking the effect of estrogen, enabling greater amounts of luteinizing hormone (LH) released by the pituitary gland. Traditional aromatase inhibitor drugs often used for gynecomastia in male bodybuilders come with significant risks to your cholesterol and in crushing your estrogen levels. So those steroids that do aromatize need to have these effects addressed; otherwise, you get out-of-control estrogen conversion, rising estrogen levels, and lower testosterone levels. In contrast, SERMs like Nolvadex, Clomid, and Toremifene are only effective at controlling gyno because these drugs were developed to target breast tissue estrogen receptors. Both are valued and used for their beneficial effects in reducing or preventing estrogen-related side effects of steroids and to assist with restoring testosterone function as part of post-cycle therapy. A clinical strategy was described that led to the creation of SERMs as a group of multifunctional medicines aimed at the treatment or prevention of many conditions in postmenopausal women, e.g. osteoporosis and breast cancer.
